{"id":"W2910542347","doi":"10.1182/blood-2018-99-110543","title":"Efficacy and Safety Following Dose Reduction of Bosutinib or Imatinib in Patients with Newly Diagnosed Chronic Myeloid Leukemia: Analysis of the Phase 3 BFORE Trial","year":2018,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Bosutinib; Medicine; Imatinib; Adverse effect; Internal medicine; Tyrosine-kinase inhibitor; Population; Tolerability; Oncology; Myeloid leukemia; Pharmacology; Nilotinib; Cancer","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002489412,0.0002179972,0.0007404549,0.0002528125,0.00007710057,0.000007471353,0.0001212203,0.0001221488,0.0000907411],"category_scores_gemma":[0.0003180596,0.000129617,0.0001944665,0.001284427,0.0002128153,0.00009173885,0.00006519674,0.0001687619,0.000001397807],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00058419,"about_ca_system_score_gemma":0.0009243766,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.000275756,"about_ca_topic_score_gemma":0.0002505209,"domain_scores_codex":[0.9981793,0.00009379958,0.0006591331,0.000359373,0.000439939,0.0002684872],"domain_scores_gemma":[0.9986645,0.000156249,0.000401597,0.0005899371,0.0001013165,0.00008641283],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.3521862,0.02288035,0.5120849,0.0006295759,0.0204145,0.00008554669,0.008450009,0.0002789458,0.01316799,0.00003974525,0.0001952151,0.06958703],"study_design_scores_gemma":[0.5652855,0.006441035,0.4131348,0.0004307147,0.007284446,0.000005548234,0.0001118649,0.0001955385,0.006918339,0.000002588099,0.00005082612,0.0001387931],"study_design_candidate":"observational","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9977345,0.0001208539,0.000006286004,0.00003727214,0.0001589146,0.001726252,0.00003979725,0.0000189679,0.0001570856],"genre_scores_gemma":[0.9991326,0.0000305773,0.0004189693,0.00001310987,0.0001825855,0.00003594418,0.00009277354,0.00002469343,0.00006874435],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.2130993,"threshold_uncertainty_score":0.5285627,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01273656362391052,"score_gpt":0.2805123147050226,"score_spread":0.2677757510811121,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}